Andrew Swayne

Epstein-Barr virus–specific T cell therapy for progressive multiple sclerosis

Michael P. Pender, Peter A. Csurhes, Corey Smith et al. · JCI Insight · 2018 · 157 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial

Jacqueline Palace, Dean M. Wingerchuk, Kazuo Fujihara et al. · Multiple Sclerosis and Related Disorders · 2020 · 40 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +15

Sustained Clinical Improvement in a Subset of Patients With Progressive Multiple Sclerosis Treated With Epstein–Barr Virus-Specific T Cell Therapy

Zara A. Ioannides, Peter A. Csurhes, Nanette L. Douglas et al. · Frontiers in Neurology · 2021 · 36 citations · Full text

Life Sciences, Immunology, Cell Therapy +13

Psychiatric management of anti-NMDAR encephalitis: a cohort analysis

Nicola Warren, Cullen O’Gorman, Gemma McKeon et al. · Psychological Medicine · 2019 · 30 citations

Medicine, Pharmacotherapy, Psychiatry +17

An Australian State-Based Cohort Study of Autoimmune Encephalitis Cases Detailing Clinical Presentation, Investigation Results, and Response to Therapy

Andrew Swayne, Nicola Warren, Kerri Prain et al. · Frontiers in Neurology · 2021 · 24 citations · Full text

Life Sciences, Immunology, Neurology +17